Orchestra BioMed to Participate in the Jefferies Global Healthcare Conference
Rhea-AI Summary
Orchestra BioMed (Nasdaq: OBIO) announced participation in the Jefferies Global Healthcare Conference. Chairman and CEO David Hochman will join a fireside chat with Jefferies Managing Director Matt Taylor at 9:55 a.m. ET on Thursday, June 4, 2026.
He will also host one-on-one investor meetings on June 3 and 4. The fireside chat will be available via live webcast on the company’s Investor Relations website, open to investors and other interested parties.
Positive
- None.
Negative
- None.
News Market Reaction – OBIO
In the May 19 session, OBIO gained 0.50%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 12 | Earnings and update | Neutral | +0.0% | Q1 2026 results, cash runway into Q4 2027, clinical progress updates. |
| May 12 | Clinical timeline update | Positive | +3.8% | BACKBEAT enrollment and data timelines plus FDA-approved sample size reduction. |
| May 06 | Financing tranche Ligand | Positive | +2.5% | Receipt of $15M Ligand tranche completing $40M capital from Ligand. |
| May 06 | Financing tranche Medtronic | Positive | +2.5% | Receipt of $20M Medtronic payment supporting BACKBEAT global pivotal trial. |
| Apr 30 | FDA designation | Positive | +5.0% | Second FDA Breakthrough Device Designation expanding AVIM Therapy indications. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive operational, regulatory, and financing updates have generally seen flat-to-positive price alignment, with no clear instances of selling on good news in the provided window.
Over the past months, OBIO reported Q1 2026 results highlighting cash, cash equivalents and marketable securities of $94.4 million and a projected cash runway into Q4 2027, alongside continued BACKBEAT and Virtue trial progress. The company secured $35 million in strategic capital from Medtronic and Ligand and received a second FDA Breakthrough Device Designation for AVIM Therapy, covering an addressable U.S. population of over 7.7 million adults. These milestones frame the conference participation within an ongoing clinical and financing execution story.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HOPE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will be participating in the Jefferies Global Healthcare Conference.
Chairman and CEO David Hochman will participate in a fireside chat with Matt Taylor, Managing Director at Jefferies at 9:55am ET on Thursday June 4, 2026 and will also host one-on-one meetings with investors that day and on Wednesday, June 3. The fireside chat will be accessible to investors and interested parties via a live webcast, which is available on Orchestra BioMed’s Investor Relations website.
About Orchestra BioMed
Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates - Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB) - are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designations for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system designed to deliver a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.
Investor Contact:
Silas Newcomb
Orchestra BioMed
Snewcomb@orchestrabiomed.com
Media Contact:
Kelsey Kirk
Orchestra BioMed
484-682-4892
Kkirkellis@orchestrabiomed.com
